Suppr超能文献

应用 MAT-CHDSP 评估经皮冠状动脉介入治疗后冠心病二级预防中的指南依从性和治疗目标达标情况。

Application of the MAT-CHDSP to assess guideline adherence and therapy goal achievement in secondary prevention of coronary heart disease after percutaneous coronary intervention.

机构信息

Hospital Pharmacy of North Norway Trust, Tromsoe, Norway.

出版信息

Eur J Clin Pharmacol. 2013 Mar;69(3):703-9. doi: 10.1007/s00228-012-1402-7. Epub 2012 Sep 19.

Abstract

PURPOSE

Numerous studies have documented suboptimal adherence to guideline recommendations in secondary prevention of coronary heart disease (CHD(SP)). Clinical practice guidelines (CPGs) are continuously developed to define appropriate patient care, aiming to reduce risk of morbidity and death. The Medication Assessment Tool for CHD(SP) (MAT-CHD(SP)) was developed to assess adherence to CPGs concerning medication therapy and follow-up of patients with CHD(SP). The aim of this study was to explore whether the MAT-CHD(SP) could be applied retrospectively to assess guideline adherence and therapy goal achievement in secondary prevention of CHD.

METHODS

We collected data from electronic medical records of all patients who underwent percutaneous coronary intervention with stent implantation from January to March 2008 (n = 300) and applied the MAT-CHD(SP). We measured time for data collection and MAT application and tested reproducibility by calculating Cohen's kappa (κ) value for inter and intraobserver agreement.

RESULTS

A total of 247 MAT applications were analyzed, showing overall applicability of 66 % of the 4,446 MAT-CHD(SP) criteria and a high reproducibility of MAT-CHD(SP) application (κ values 0.93 and 0.95 for intra- and interobserver agreement, respectively). Mean time for data collection and MAT-CHD(SP) application was 11 min. Adherence to criteria concerning prescription was high (>75 %), but achievement of therapy goals for cholesterol and blood pressure was low (<50 %). Documentation of lifestyle advice achieved intermediate (50-75 %) or low adherence, as did therapy amendments in patients in whom therapy goals were unachieved at hospital admission.

CONCLUSIONS

The MAT-CHD(SP) offers a means to identify both adherence and nonadherence to CPGs concerning CHD(SP) is applicable in retrospective assessment of CHD(SP), and identifies potentials for improved patient care.

摘要

目的

大量研究记录表明,在冠心病(CHD)二级预防中,指南推荐的依从性并不理想。临床实践指南(CPG)不断发展,旨在为患者提供适当的医疗服务,以降低发病率和死亡率。冠心病二级预防用药评估工具(MAT-CHD(SP))是为评估冠心病二级预防患者药物治疗和随访的依从性而开发的。本研究旨在探讨 MAT-CHD(SP)是否可以用于回顾性评估 CHD 二级预防的指南依从性和治疗目标的达成。

方法

我们从 2008 年 1 月至 3 月接受经皮冠状动脉介入治疗(PCI)的所有患者的电子病历中收集数据(n=300),并应用 MAT-CHD(SP)。我们测量了数据收集和 MAT 应用的时间,并通过计算组内和组间观察者一致性的 Cohen's kappa(κ)值来测试重复性。

结果

共分析了 247 次 MAT 应用,结果显示 4446 项 MAT-CHD(SP)标准中,总体适用性为 66%,MAT-CHD(SP)应用的重复性很高(组内和组间观察者一致性的κ值分别为 0.93 和 0.95)。数据收集和 MAT-CHD(SP)应用的平均时间为 11 分钟。关于处方的标准的依从性很高(>75%),但胆固醇和血压的治疗目标的达标率较低(<50%)。生活方式建议的记录达到中等(50-75%)或低水平,在入院时治疗目标未达到的患者中进行治疗调整也是如此。

结论

MAT-CHD(SP)提供了一种识别冠心病二级预防 CPG 依从性和不依从性的方法,可用于 CHD(SP)的回顾性评估,并确定了改善患者护理的潜力。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验